Abstract:Despite recent progress, the challenges in drug discovery for schizophrenia persist. However, computational drug repurposing has gained popularity as it leverages the wealth of expanding biomedical databases. Network analyses provide a comprehensive understanding of transcription factor (TF) regulatory effects through gene regulatory networks, which capture the interactions between TFs and target genes by integrating various lines of evidence. Using the PANDA algorithm, we examined the topological variances in TF-gene regulatory networks between individuals with schizophrenia and healthy controls. This algorithm incorporates binding motifs, protein interactions, and gene co-expression data. To identify these differences, we subtracted the edge weights of the healthy control network from those of the schizophrenia network. The resulting differential network was then analysed using the CLUEreg tool in the GRAND database. This tool employs differential network signatures to identify drugs that potentially target the gene signature associated with the disease. Our analysis utilised a large RNA-seq dataset comprising 532 post-mortem brain samples from the CommonMind project. We constructed co-expression gene regulatory networks for both schizophrenia cases and healthy control subjects, incorporating 15,831 genes and 413 overlapping TFs. Through drug repurposing, we identified 18 promising candidates for repurposing as potential treatments for schizophrenia. The analysis of TF-gene regulatory networks revealed that the TFs in schizophrenia predominantly regulate pathways associated with energy metabolism, immune response, cell adhesion, and thyroid hormone signalling. These pathways represent significant targets for therapeutic intervention. The identified drug repurposing candidates likely act through TF-targeted pathways. These promising candidates, particularly those with preclinical evidence such as rimonabant and kaempferol, warrant further investigation into their potential mechanisms of action and efficacy in alleviating the symptoms of schizophrenia.

A machine learning approach to drug repositioning based on drug expression profiles: Applications to schizophrenia and depression/anxiety disorders

Machine learning for drug repositioning: Recent advances and challenges

Machine Learning and Deep Learning Strategies in Drug Repositioning

Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity.

A Pathway Profile-Based Method for Drug Repositioning

Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

A New Approach to Drug Repurposing with Two-Stage Prediction, Machine Learning, and Unsupervised Clustering of Gene Expression

Discovery of Novel Therapeutic Properties of Drugs from Transcriptional Responses Based on Multi-Label Classification

deepDR: a network-based deep learning approach to in silico drug repositioning

DrugRepPT: a Deep Pre-Training and Fine-Tuning Framework for Drug Repositioning Based on Drug's Expression Perturbation and Treatment Effectiveness.

Network-based drug repurposing for schizophrenia

Computational Drug Repositioning Using Collaborative Filtering Via Multi-Source Fusion

A Computational Strategy for Drug Repositioning Based on Support-Vector Regression Algorithm

Network-based drug repositioning: A novel strategy for discovering potential antidepressants and their mode of action

A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus

Drug repositioning for psychiatric and neurological disorders through a network medicine approach

novel approach of drug repurposing in immuno-oncology therapeutic agents using machine learning algorithm

Computational Drug Repositioning Using Meta-Path-based Semantic Network Analysis.

Drug Repositioning By Kernel-Based Integration Of Molecular Structure, Molecular Activity, And Phenotype Data

Deep learning in target prediction and drug repositioning: Recent advances and challenges